Skip to content

EBIT at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
-$34.21M+2.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$57.52M+8.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.33M-54.4%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's EBIT?
Xencor (XNCR) reported EBIT of -$77.86M in Q1 2026.
How has Xencor's EBIT changed year-over-year?
Xencor's EBIT decreased by 80.3% year-over-year, from -$43.18M to -$77.86M.
What is the long-term trend for Xencor's EBIT?
Over 4 years (2021 to 2025), Xencor's EBIT has grown at a 41.9% compound annual growth rate (CAGR), from $43.77M to -$177.5M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.